ERBB2 and extramammary Paget disease: Therefore, although the patient did not take the FISH test, we decided to have an attempt about disitamab vedotin in EMPD with Her-2 overexpression given the promising efficacy of disitamab vedotin in Her-2–positive solid tumor.